CID24856225
CID24856225 性质
| 沸点 | 422.8±48.0 °C(Predicted) |
|---|---|
| 密度 | 1.330±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 二甲基亚砜：≥5mg/mL |
| 酸度系数(pKa) | -3.45±0.40(Predicted) |
| 形态 | 膜状 |
| 颜色 | 无色 |
| InChI | 1S/C17H20N2O5/c1-23-15(21)18-14(20)17(13-10-6-7-11-13,19(18)16(22)24-2)12-8-4-3-5-9-12/h3-5,8-9,13H,6-7,10-11H2,1-2H3/t17-/m0/s1 |
| InChIKey | ZRHWCAFAIHTQKD-KRWDZBQOSA-N |
| SMILES | O=C1[C@](C2=CC=CC=C2)(C3CCCC3)N(C(OC)=O)N1C(OC)=O |
CID24856225 用途与合成方法
IC50: 6.4 nM (PME-1 in HEK293T), 4.2 nM (PME-1 in MDA-MB-231)
Three described PME-1 inhibitors are tested in this assay and a thermal shift with 100 μM ABL127 is detected. Using 25 or 50 μM ABL127 also shows a shift in protein melting temperature. It is found that treatment of Ishikawa cells with ABL127 and AMZ-30 significantly decreases cell proliferation similarly to depletion of PME-1 with shRNA. It is also found that treatment of ECC-1 cells with ABL127 or AMZ-30 affects cell invasion in a dose-dependent manner. The treatment of EC cells with ABL127 leads to a significant ~45 % increase in protein phosphatase 2A (PP2A) activity, while treatment with AMZ-30 leads to a modest ~10 % increase in PP2A activity.
No significant decrease in tumor burden can be assessed in these pilot studies. Gel-based profiles indicate that brain PME-1 is inactivated by ABL127, but overlapping serine hydrolase activities preclude a confident assessment of the extent of inactivation.
CID24856225 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-12-22 | HY-108317 | 1073529-41-5 | 1 mg | 1704 | |
| 2025-12-22 | HY-108317 | CID24856225 | 1073529-41-5 | 5mg | 3750 |
